Endpoints News
Endpoints News published an extensive article on the results of our Phase 2/3 study of RT001 in patients with INAD. The article offers great context for the study data, as well as our plans for pursuing a potential regulatory approval pathway for the treatment in this ultra-rare disease with no current treatment options.